Whether lorlatinib has been included in the national medical insurance directory

Lorlatinib (Lolatinib) is a third-generation ALK tyrosine kinase inhibitor, mainly used to treat ALK Positive non-small cell lung cancer (NSCLC) patients, especially those who are resistant to first- and second-generation ALK inhibitors, have a significant effect in treatment. With its widespread clinical recognition, lorlatinib has been officially launched in mainland China and has been included in the National Reimbursement Directory, which has brought a more accessible and economical treatment option to the majority of patients with ALK-positive lung cancer.

After the successful negotiation of medical insurance, the price of lorlatinib has been significantly reduced, but even so, its price before medical insurance is still relatively high, with each box selling for about 10,000 to 20,000 yuan. The specific price for patients depends on factors such as the medical insurance reimbursement ratio, regional policies, and hospital levels. It is recommended that patients go to the local medical insurance designated hospital pharmacy for detailed consultation to obtain the most accurate reimbursement amount and process information.

In addition to the domestic version, the original drug and generic version of lorlatinib are also available on the market through overseas channels. Among them, the Turkish version of the original drug has attracted the attention of many patients due to its lower price (approximately more than 7,000 yuan). Although the Hong Kong version is of original quality, it is priced at a higher price of about 30,000 yuan, which is suitable for patients with a higher budget and who pursue original quality. It is worth mentioning that the generic version of the drug in Laos and Bangladesh is also widely circulated. The price is only more than one thousand yuan, which is extremely cost-effective. Its active ingredients are basically the same as the original drug, which can meet the needs of patients with greater financial pressure to a certain extent.

In general, lorlatinib has been included in the national medical insurance catalog, which has greatly reduced the medication burden for some patients, but it still belongs to the category of high-priced targeted drugs. When choosing medication, patients can flexibly choose domestic formal channels or overseas compliant generic drug procurement methods based on medical insurance reimbursement status, their own financial situation and doctor's advice to ensure the continuity, safety and effectiveness of treatment. No matter which version you choose, be sure to purchase it through formal channels to ensure the quality of the medicine and avoid medication errors that may affect the therapeutic effect.

Reference materials:https://www.drugs.com/